Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.37 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.37 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.32 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12885928 | 1.00 | GABRR1 (0.42) | GABRR1CYP1A2FOLH1NAALAD2ENPEP | |
| SCHEMBL5960707 | 1.00 | GABRR1 (0.42) | GABRR1CYP1A2FOLH1NAALAD2ENPEP | |
| Pyridine SCHEMBL28275234 | 0.84 | TBXAS1 (0.39) | GABRR1CYP1A2ALDH1A1 | |
| SCHEMBL10266069 | 0.82 | GABRR1 (0.41) | GABRR1CYP1A2FOLH1NAALAD2ENPEP | |
| SCHEMBL19918461 | 0.82 | GABRR1 (0.41) | GABRR1CYP1A2FOLH1NAALAD2ENPEP | |
| SCHEMBL15905686 | 0.82 | GABRR1 (0.41) | GABRR1CYP1A2FOLH1NAALAD2ENPEP | |
| SCHEMBL9438162 | 0.80 | GABRR1 (0.39) | GABRR1CYP1A2FOLH1NAALAD2ENPEP | |
| SCHEMBL1766737 | 0.80 | GABRR1 (0.39) | GABRR1CYP1A2FOLH1NAALAD2ENPEP | |
| SCHEMBL27335599 | 0.80 | GABRR1 (0.39) | GABRR1CYP1A2FOLH1NAALAD2ENPEP | |
| SCHEMBL14281509 | 0.79 | ALDH1A1 (0.32) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117441254-A | Electrolyte for secondary battery, and electronic device | 宁德新能源科技有限公司 | 2024-01-23 | — | — | CN | claimed |
| CN-116706232-A | Electrolyte of secondary battery, secondary battery and electronic device | 宁德新能源科技有限公司 | 2023-09-05 | — | — | CN | claimed |
| EP-2212964-B1 | NON-AQUEOUS ELECTROLYTE LITHIUM SECONDARY BATTERY | LG CHEMICAL LTD (KR) | 2017-06-21 | — | — | EP | claimed |
| EP-2304837-B1 | CYLINDRICAL LITHIUM SECONDARY BATTERY | LG CHEMICAL LTD (KR) | 2017-01-04 | — | — | EP | claimed |
| EP-2238643-B1 | POUCH-TYPE LITHIUM SECONDARY BATTERY | LG CHEMICAL LTD (KR) | 2014-03-26 | — | — | EP | claimed |
| EP-2266159-B1 | NON-AQUEOUS ELECTROLYTE SOLUTION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY COMPRISING THE SAME | LG CHEMICAL LTD (KR) | 2013-10-23 | — | — | EP | claimed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| EP-0489548-B1 | A process for the preparation of 2(R)-methyl-4,4,4-trifluorobutylamine, intermediates, and a process for the preparation of a derivative thereof | ZENECA LTD (GB) | 1994-12-14 | — | — | EP | claimed |
| US-5274118-A | Process for preparing (2R)-methyl-4,4,4-trifluorobutylamine | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-12-28 | — | — | US | claimed |
| EP-0489548-A1 | A process for the preparation of 2(R)-methyl-4,4,4-trifluorobutylamine, intermediates, and a process for the preparation of a derivative thereof | ZENECA LIMITED (GB) | 1992-06-10 | — | — | EP | claimed |
| JP-4290870-A | — | — | None | — | — | JP | disclosed |
| EP-4747245-A1 | PHARMACEUTICAL COMPOUNDS | Almac Discovery Limited (GB) | 2026-05-27 | — | — | EP | disclosed |
| US-20260103459-A1 | SUBSTITUTED AZACYLES AS TRPM8 MODULATORS | GIVAUDAN SA (CH) | 2026-04-16 | — | — | US | disclosed |
| US-12528801-B2 | Substituted azacyles as TRPM8 modulators | GIVAUDAN SA (CH) | 2026-01-20 | — | — | US | disclosed |
| US-12466805-B2 | Pharmaceutical compounds | ALMAC DISCOVERY LIMITED (GB) | 2025-11-11 | — | — | US | disclosed |
| JP-H04290870-A | PRODUCTION METHOD | IMPERIAL CHEM IND PLC <ICI> | 1992-10-15 | — | — | JP | disclosed |
| EP-0489548-A1 | A process for the preparation of 2(R)-methyl-4,4,4-trifluorobutylamine, intermediates, and a process for the preparation of a derivative thereof | ZENECA LIMITED (GB) | 1992-06-10 | — | — | EP | disclosed |
| EP-0489548-A1 | A process for the preparation of 2(R)-methyl-4,4,4-trifluorobutylamine, intermediates, and a process for the preparation of a derivative thereof | ZENECA LIMITED (GB) | 1992-06-10 | — | — | EP | disclosed |
| EP-0489547-A1 | A process for the preparation of a 3-alkylated indole, intermediates, and a process for the preparation of a derivative thereof | ZENECA LIMITED (GB) | 1992-06-10 | — | — | EP | disclosed |
| EP-0432984-A2 | Carbamoyl derivatives | ZENECA LIMITED (GB) | 1991-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103459-A1 | SUBSTITUTED AZACYLES AS TRPM8 MODULATORS | TRPM8, TRPM7, TRPM5 | GABRR1 1235/4885CYP1A2 1434/4885FOLH1 4696/4885 |
| US-12466805-B2 | Pharmaceutical compounds | USP19, USP18, UBE2I | GABRR1 2775/4885CYP1A2 805/4885FOLH1 603/4885 |
| US-12528801-B2 | Substituted azacyles as TRPM8 modulators | TRPM8, TRPM7, TRPM4 | GABRR1 1286/4885CYP1A2 1702/4885FOLH1 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.